Skip to main content
$0.76 $0.02 (2.3%)

04:00 PM EST on 12/08/23

Assembly Biosciences (NASDAQ:ASMB)

CAPS Rating: No stars

Current Price $0.76 Mkt Cap $49.9M
Open $0.74 P/E Ratio -0.53
Prev. Close $0.76 Div. (Yield) $0.00 (0.0%)
Daily Range $0.72 - $0.77 Volume 215,926
52-Wk Range $0.64 - $1.78 Avg. Daily Vol. 1,922,789


How do you think NASDAQ:ASMB will perform against the market?

Add Stock to CAPS Watchlist

All Players

24 Outperform
9 Underperform

All-Star Players

1 Outperform
3 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:ASMB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

corkbouy (< 20)
Submitted July 21, 2011

The clearance will soon come from the fed. for this the first drug of its kind. Now Dr.s can prescribe a med for this type of problem.

drugtrader (44.20)
Submitted March 04, 2015

Temporary red thumb. Likely resistance above this price. However, the receptor described in the score leader taunt is actually a useful pathway for treating inflammation and may prove positive in trials.The company was previously known as Ventrus… More

Fools bullish on NASDAQ:ASMB are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ASMB.


Member Avatar rhallbick (91.32) Submitted: 5/9/2018 6:48:40 AM : Outperform Start Price: $54.47 NASDAQ:ASMB Score: -168.93

Assembly Biosciences, Inc. (NASDAQ Capital Market: ASMB)
Thesis: Speculative CAPS-only pick, not a recommendation. Company prospects are down somewhat since pick was made.
Assembly Biosciences (ASMB) was created in mid-2014 when publicly-traded dollar-stock, Ventrus Biosciences Inc. (NASDAQ: VTUS), acquired privately-owned Assembly Pharmaceuticals, Inc. in an all-stock deal. On the same day, the merged company effected a 1-for-5 reverse stock split, raising its shares out of the penny-stock realm. The company also changed its name to Assembly Biosciences, and began trading on NASDAQ under the symbol ASMB.

ASMB has legacy developmental products from Ventrus, who had focused on developing and commercializing drugs for gastrointestinal disorders; specifically hemorrhoids, anal fissures, and fecal incontinence. They have a collaboration agreement with Allergan Pharmaceuticals Int'l Ltd. for the development and commercialization of selected microbiome gastrointestinal programs.

The former Assembly Pharmaceuticals was developing a new class of oral small-molecule therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. Specifically, they were, and are, involved in the development of core protein allosteric modulators (CpAM) that modulate the HBV core protein at various points in the viral lifecycle.

ASMB has released interim data on a Phase 1b/2a study of their novel CpAM candidate ABI-H0731 for the treatment of chronic HBV infection. The data is encouraging, as the drug is seen as effective, generally safe and well tolerated, and no dose limiting side effects were seen.

Competitors of ASMB with similar-acting drugs have also been releasing their own Phase II study data with similar results, so ASMB does not stand out as having the superior drug at this time. Johnson & Johnson is developing JNJ-56136379, Hoffmann-La Roche is developing RO7049389, and Spring Bank Pharmaceuticals is developing inarigivir soproxil (formerly known as SB 9200).

There are currently effective treatments in the marketplace for HBV, but not yet a functional cure. The goal is to find a drug combination that will permanently cure HBV infected patients. Combination therapies in Phase II studies may provide for an aseptic cure, but it is not clear now which company or companies will be successful. Many years of drug development still lay ahead of them.

Stock is covered by at least six analysts with a $45-$84 price target range (average $58.00). Higher estimates may be from before the Apr 12th EASL’s 2018 International Liver Congress, where ASMB, Johnson & Johnson and Hoffmann-La Roche all presented some of their Phase II data for their similar drugs, and ASMB was found not to have any significant advantages over their competitors, and to be slightly behind in the progress of their trials.

As of May 2, 2018, there were 20,550,718 common stock shares outstanding.
Short interest reported on Apr 13, 2018 was 502,904 shares, which is 2.4% of total shares.

Price: $54.47 | Annual Dividend: $0.00 | Dividend Yield: 0.00%


Member Avatar ptanabe (63.34) Submitted: 8/5/2013 2:23:20 PM : Outperform Start Price: $12.77 NASDAQ:ASMB Score: -263.62



Member Avatar carefulguy (< 20) Submitted: 11/16/2011 1:37:23 AM : Outperform Start Price: $40.75 NASDAQ:ASMB Score: -366.83

Currently undervalued based on large market potential of a Hemorrhoids treatment (first to market - currently no treatment available). Good cash balance, and upcoming Q2 2012 PIII pivotal clinical trial results of two drugs. Currently trading at very low volume, once interest picks up, pps will go up.


Find the members with the highest scoring picks in ASMB.

Score Leader


williamstep (97.83) Score: +348.05

The Score Leader is the player with the highest score across all their picks in ASMB.

Member Name Member
Call Time
Score Commentary
williamstep 97.83 5/23/2011 Underperform 5Y $87.80 -99.12% +248.93% +348.05 0 Comment
EclecticRecluse < 20 5/16/2011 Underperform 3W $97.35 -99.21% +244.56% +343.77 1 Comment
IdahoInvestor 99.58 11/15/2012 Underperform 5Y $10.75 -92.85% +238.43% +331.28 0 Comment
CocaineOrStock 92.57 7/15/2014 Underperform 5Y $9.15 -91.60% +133.21% +224.81 0 Comment
mrblond2 23.30 7/23/2014 Underperform 3W $7.14 -89.23% +131.84% +221.08 0 Comment
rothenbr 50.10 8/22/2016 Underperform 3Y $6.50 -88.17% +110.85% +199.02 0 Comment
tycoon24 57.68 9/1/2017 1/5/2021 Underperform 1Y $27.24 -97.18% +85.40% +182.57 0 Comment
Momentum21 34.19 10/4/2017 Underperform 5Y $35.00 -97.80% +81.93% +179.74 0 Comment
WildShaman 78.17 7/5/2018 Underperform 5Y $39.67 -98.06% +69.09% +167.15 0 Comment
mcvolunteer 27.05 11/30/2021 Outperform 5Y $2.24 -65.67% +0.65% -66.32 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ASMB.